/NOT FOR DISTRIBUTION IN THE UNITED
STATES OR THROUGH UNITED
STATES WIRE SERVICES./
TORONTO,
Nov. 2, 2012 /CNW/ - Microbix
Biosystems Inc. (TSX:MBX) is pleased to announce it has made
application to the TSX to extend the term and amend the exercise
price of an aggregate of 3,250,000 common share purchase warrants
(the "Warrants") which were issued in connection with Microbix's
November 13, 2007 private
placement.
Each Warrant currently entitles the holder to
purchase one common share of Microbix at a price of $1.26 until November 13,
2012. Microbix has applied to the TSX to extend the
term of the Warrants to November 13,
2013 and to re-price the Warrants from $1.26 to $0.40 per share.
The holders of the Warrants are all arm's length
to Microbix. The amendments to the Warrants are subject to TSX
approval.
The Toronto Stock Exchange does not accept
responsibility for the adequacy or accuracy of this release.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the
development of the most advanced vaccine production technology and
markets virology and biological products worldwide. In addition,
The Company has intellectual property in large market
biotherapeutic drugs, vaccine technologies and animal reproduction
technologies. Microbix supplies customers in the U.S., Europe, and Asia. Established in 1988, Microbix is
headquartered in Toronto.
Disclaimer
This press release may contain forward-looking
statements which are subject to risks and uncertainties that could
cause actual results to differ materially from those set forth in
the forward-looking statements including the risks associated with
development projects, operations in foreign jurisdictions, risks
associated with engineering and construction generally, risks
associated with production including control over costs, quality,
quantity and timeliness of delivery of products, foreign currency
and exchange rate risk, and risks of raising capital on acceptable
terms or at all. These forward-looking statements represent
the Company's judgment as of the date of this press release. The
Company disclaims any intent or obligation to update these
forward-looking statements.
SOURCE Microbix Biosystems Inc.
